viewCytoDyn Inc.

Full interview: CytoDyn looks to FDA to green light Phase 2 trials of leronlimab to treat colon cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech has filed a Phase 2 protocol with the Food and Drug Administration for a combination therapy of leronlimab and regorafenib to treat patients with metastatic colorectal cancer.

Dr Pourhassan explains that the Vancouver, Washington-based biotechnology company's animal studies with this indication show "strong results" so there is no reason why CytoDyn should not progress to Phase 2 trials.

Quick facts: CytoDyn Inc.

Price: 2.83 USD

Market: OTCQB
Market Cap: $1.36 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



CytoDyn continues to works on licensing deals as FDA continues its review on...

CytoDyn (OTCQB: CYDY) President and Chief Executive Officer Nader Pourhassan joined Steve Darling from Proactive to discuss a number of issues including the very latest on their clinical trials for a COVID-19 treatment. Pourhassan also told Proactive that they are in discussions with numerous...

6 hours, 26 minutes ago

2 min read